Ropes & Gray Advises CAMP4 Therapeutics on IPO

Ropes & Gray represented CAMP4 Therapeutics in its $75 million initial public offering on the Nasdaq Global Market under the trading symbol “CAMP” which priced on Oct. 10 in an offering of 6.82 million shares of common stock at an IPO price of $11.00 per share and was announced in a news release.

CAMP4 Therapeutics is developing disease-modifying treatments for a broad range of genetic diseases in a therapeutic process to increase certain protein levels by targeting regulatory RNA sequences, which are key elements controlling gene expression.

Last month, Ropes & Gray represented clients in two life sciences IPOs which priced on Sept. 12 for an aggregate value of $540 million. Among the deals Ropes & Gray was involved in were the following:

1. Represented the underwriters in Bicara Therapeutics’ $315 million initial public offering. The transactions is the third-largest life sciences IPO of the year, according to BioPharma Dive data and was announced in a press release. The deal team included capital markets partner Tom Danielski and counsel Ray Grant.
2. Represented Zenas BioPharma in its $225 million initial public offering was announced in a press release. The deal team included capital markets partner Tom Danielski and counsel Nicholas Roper, executive compensation & employee benefits partner Ellen Sueda, health care partner Eve Brunts, and life sciences regulatory & compliance partner Kellie Combs.

The Ropes & Gray CAMP4 IPO deal team included capital markets partner Tom Danielski, life sciences partner Marc Rubenstein and capital markets associate Lisa Folkerth, employment & benefits partner Renata Ferrari, life sciences regulatory & compliance partner Kellie Combs and health care counsel Alison Fethke.